PJP prophylaxis in GPA. Always a trade off but these things are not created equal. PJP or sepsis are much worse on average than the AEs @anisha_dua @RheumNow #RNL2024 https://t.co/9sECd7fSRk

Remission maintenance in AAV. First 2 years is clear - fixed dose RTX is superior. After that it is clear that following ANCA is suboptimal, could consider either B-cell return dosing or ongoing fixed dosing @anisha_dua @RheumNow #RNL2024 https://t.co/0Elir88L9U

Maintenance issues in GPA. Clear messages. 1. RTX is best 2. Fixed 6-monthly RTX best for 1st 2 years. 3. Don't stop RTX at 2 years! @anisha_dua @RheumNow #RNL2024 https://t.co/jS3jWm0CcS

The answer to "always" is "always" no, correct? PEXIVAS low dose is a great baseline plan, but always adjust in light of the individual patient both upfront and especially if things aren't working out @anisha_dua @RheumNow #RNL2024 https://t.co/RPnpAdB1eG

Rapid GC taper in ANCA vasculitis #RNL2024 @RheumNow @anisha_dua PEXIVAS - reduced GC is safe, decreased ifns Retrospective real world - 234 pts. Reduced dose GC+RTX increased death/ESKD HR 2.42. No difference in infections https://t.co/SWIUSyVbWb

Great talk @anisha_dua re:AAV, solid updates on mgmt decisions Looking forward to debating this study with @lastwalsh w/@MatsJunek moderating... @TerrierBen any updates on when your RWD study will be published? @RheumNow https://t.co/ywVaOIp2WJ

Contrasing ACR/VF and EULAR GPA guidelines from @anisha_dua @RheumNow #RNL2024 https://t.co/RLJx9fJHGk

"Real world studies: When people stop being polite and start getting real." Dr @anisha_dua #RNL2024 Comparing Walsh to Nagle in terms of primary outcomes, regimens, pt populations, and plasma exchange. @RheumNow https://t.co/io8OGnWxdS

Is there data for PLEX in GPA? @anisha_dua #RNL2024 @RheumNow PEXIVAS negative study But subgroups show decreased dialysis... But, no improvement in mortality and increased infection risk https://t.co/K9VbcNNsge

#RNL2024 @RheumNow @anisha_dua Throwing the kitchen sink in severe GPA CYC + RTX combo - sick population (median GFR 9, 47% on HD, 52% DAH, all received PLEX too) - 85% survival, 69% not ESKD, low rates of relapse (13% at 36 mos) But, prolonged B cell depletion, aggressive Rx https://t.co/9AZFMQ3o9P

#RNL2024 is up and at ‘em this Sunday morning! ⁦@RheumNow⁩ ⁦@KDAO2011⁩ ⁦@RichardPAConway⁩ ⁦@ericdeinmd⁩ https://t.co/AtL9QiRnW4

@anisha_dua reviews differences between EULAR vs ACR Vasculitis guidelines #RNL2024 @RheumNow https://t.co/1aIbnX5KBI